In silico screening for inhibitors of P-glycoprotein that target the nucleotide binding domains

Molecular Pharmacology

Volumn 86, Issue 6, 2014, Pages 716-726

  Brewer, Frances K ^a   Follit, Courtney A ^a   Vogel, Pia D ^a   Wise, John G ^a  

^a SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; FLAVONOL DERIVATIVE; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; NUCLEOTIDE;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ELECTRON SPIN RESONANCE; HIGH THROUGHPUT SCREENING; HUMAN; HYDROLYSIS; LIGAND BINDING; MOLECULAR DOCKING; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ADENOSINE TRIPHOSPHATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; HYDROLYSIS; MOLECULAR DOCKING SIMULATION; NUCLEOTIDES; P-GLYCOPROTEIN; PROTEIN STRUCTURE, TERTIARY;

EID: 84937595293     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.095414     Document Type: Article

References (52)

1. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, and Urbatsch IL et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722.
2. Amaro RE, Schnaufer A, Interthal H, Hol W, Stuart KD, and McCammon JA (2008) Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc Natl Acad Sci USA 105:17278-17283.
3. Badhan R and Penny J (2006) In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur J Med Chem 41:285-295.
4. Binkhathlan Z and Lavasanifar A (2013) P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 13:326-346.
5. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, and Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
6. Copeland RA (2000) Enzymes: a Practical Introduction to Structure, Mechanism, and Data Analysis, 2nd ed. Wiley, New York.
7. Copeland RA (2013) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, 2nd ed. Wiley, Hoboken, NJ.
8. Dawson RJP and Locher KP (2006) Structure of a bacterial multidrug ABC transporter. Nature 443:180-185.
9. Dawson RJP and Locher KP (2007) Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 581: 935-938.
10. Delannoy S, Urbatsch IL, Tombline G, Senior AE, and Vogel PD (2005) Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy. Biochemistry 44:14010-14019.
11. Dey S, Ramachandra M, Pastan I, Gottesman MM, and Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94:10594-10599.
12. Di Pietro A, Conseil G, Pérez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E, Jault JM, de Wet H, and Maitrejean M et al. (2002) Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59:307-322.
13. Ford JM and Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199.
14. Goodsell DS, Morris GM, and Olson AJ (1996) Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 9:1-5.
15. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
16. Gros P, Ben Neriah YB, Croop JM, and Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728-731.
17. Harris AL and Hochhauser D (1992) Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31:205-213.
18. Hoffman AD, Urbatsch IL, and Vogel PD (2010) Nucleotide binding to the human multidrug resistance protein 3, MRP3. Protein J 29:373-379.
19. Hollenstein K, Dawson RJP, and Locher KP (2007) Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol 17:412-418.
20. Irwin JJ and Shoichet BK (2005) ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177-182.
21. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, and Coleman RG (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52:1757-1768.
22. Jin MS, Oldham ML, Zhang Q, and Chen J (2012) Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 490:566-569.
23. Kartner N and Ling V (1989) Multidrug resistance in cancer. Sci Am 260:44-51.
24. Lee J-Y, Urbatsch IL, Senior AE, and Wilkens S (2008) Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. J Biol Chem 283:5769-5779.
25. Lerner-Marmarosh N, Gimi K, Urbatsch IL, Gros P, and Senior AE (1999) Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins. J Biol Chem 274:34711-34718.
26. Li J, Jaimes KF, and Aller SG (2014) Refined structures of mouse P-glycoprotein. Protein Sci 23:34-46.
27. Loo TW, Bartlett MC, and Clarke DM (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278:39706-39710.
28. Loo TW, Bartlett MC, and Clarke DM (2009) Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis. J Biol Chem 284:24074-24087.
29. Lugo MR and Sharom FJ (2005) Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry 44:14020-14029.
30. Morris GM, Goodsell DS, Huey R, and Olson AJ (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10:293-304.
31. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, and Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30:2785-2791.
32. Osterberg F, Morris GM, Sanner MF, Olson AJ, and Goodsell DS (2002) Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 46:34-40.
33. Palmeira A, Sousa E, Vasconcelos MH, and Pinto MM (2012) Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 19:1946-2025.
34. Persidis A (1999) Cancer multidrug resistance. Nat Biotechnol 17:94-95.
35. Qu Q, Russell PL, and Sharom FJ (2003) Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle. Biochemistry 42:1170-1177.
36. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, and Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538-4542.
37. Schmidt M, Teitge M, Castillo ME, Brandt T, Dobner B, and Langner A (2008) Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents. Arch Pharm (Weinheim) 341:624-638.
38. Schmidt M, Ungvári J, Glöde J, Dobner B, and Langner A (2007) New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance. Bioorg Med Chem 15:2283-2297.
39. Shapiro AB and Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137.
40. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, and Bevan P (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD561 lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191.
41. Tombline G, Urbatsch IL, Virk N, Muharemagic A, White LB, and Senior AE (2006) Expression, purification, and characterization of cysteine-free mouse P-glycoprotein. Arch Biochem Biophys 445:124-128.
42. Urbatsch IL, Beaudet L, Carrier I, and Gros P (1998) Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. Biochemistry 37:4592-4602.
43. Urbatsch IL, Tyndall GA, Tombline G, and Senior AE (2003) P-glycoprotein catalytic mechanism: studies of the ADP-vanadate inhibited state. J Biol Chem 278:23171-23179.
44. Verhalen B, Ernst S, Börsch M, and Wilkens S (2012) Dynamic ligand-induced conformational rearrangements in P-glycoprotein as probed by fluorescence resonance energy transfer spectroscopy. J Biol Chem 287:1112-1127.
45. Verhalen B and Wilkens S (2011) P-glycoprotein retains drug-stimulated ATPase activity upon covalent linkage of the two nucleotide binding domains at their C-terminal ends. J Biol Chem 286:10476-10482.
46. Vogel G and Steinhart R (1976) ATPase of Escherichia coli: purification, dissociation, and reconstitution of the active complex from the isolated subunits. Biochemistry 15:208-216.
47. Walker J, Martin C, and Callaghan R (2004) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40:594-605.
48. Ward A, Reyes CL, Yu J, Roth CB, and Chang G (2007) Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc Natl Acad Sci USA 104:19005-19010.
49. Wen PC and Tajkhorshid E (2008) Dimer opening of the nucleotide binding domains of ABC transporters after ATP hydrolysis. Biophys J 95:5100-5110.
50. Wise JG (2012) Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51:5125-5141.
51. Zoghbi ME and Altenberg GA (2013) Hydrolysis at one of the two nucleotide-binding sites drives the dissociation of ATP-binding cassette nucleotide-binding domain dimers. J Biol Chem 288:34259-34265.
52. Zoghbi ME and Altenberg GA (2014) ATP binding to two sites is necessary for dimerization of nucleotide-binding domains of ABC proteins. Biochem Biophys Res Commun 443:97-102.